- Home
- IMPP vs CHRS Comparison
IMPP vs CHRS Comparison
Compare IMPP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- CHRS
- Stock Information
- Founded
- IMPP 1981
- CHRS 2010
- Country
- IMPP Greece
- CHRS United States
- Employees
- IMPP N/A
- CHRS N/A
- Industry
- IMPP Marine Transportation
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMPP Consumer Discretionary
- CHRS Health Care
- Exchange
- IMPP Nasdaq
- CHRS Nasdaq
- Market Cap
- IMPP 103.9M
- CHRS 102.0M
- IPO Year
- IMPP N/A
- CHRS 2014
- Fundamental
- Price
- IMPP $3.14
- CHRS $1.04
- Analyst Decision
- IMPP
- CHRS Buy
- Analyst Count
- IMPP 0
- CHRS 3
- Target Price
- IMPP N/A
- CHRS $4.68
- AVG Volume (30 Days)
- IMPP 131.7K
- CHRS 1.3M
- Earning Date
- IMPP 08-26-2025
- CHRS 08-07-2025
- Dividend Yield
- IMPP N/A
- CHRS N/A
- EPS Growth
- IMPP N/A
- CHRS N/A
- EPS
- IMPP 1.21
- CHRS N/A
- Revenue
- IMPP $138,368,325.00
- CHRS $272,251,000.00
- Revenue This Year
- IMPP $8.79
- CHRS N/A
- Revenue Next Year
- IMPP $40.11
- CHRS $99.43
- P/E Ratio
- IMPP $2.59
- CHRS $2.44
- Revenue Growth
- IMPP N/A
- CHRS 19.87
- 52 Week Low
- IMPP $2.12
- CHRS $0.66
- 52 Week High
- IMPP $4.55
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- IMPP 50.23
- CHRS 68.96
- Support Level
- IMPP $2.99
- CHRS $0.88
- Resistance Level
- IMPP $3.29
- CHRS $1.06
- Average True Range (ATR)
- IMPP 0.12
- CHRS 0.07
- MACD
- IMPP -0.01
- CHRS 0.02
- Stochastic Oscillator
- IMPP 47.06
- CHRS 93.38
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.